UBS Group’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
Other funds holding HAE
UBS Group's HAE Position: Q3 2026 in Review
UBS Group increased its Haemonetics (HAE) stake by 14% in Q3 2026, buying an estimated $12.6M and bringing the position to 1,119,167 shares worth $118M. The position accounts for 0.02% of the portfolio, ranked #991.
UBS Group first reported a position in HAE in Q2 2013 and has held it in 54 quarters since. 361 funds tracked by Wall St. Rank hold HAE as of Q3 2026.
- UBS Group held 1,119,167 shares of Haemonetics worth $118M as of Q3 2026.
- UBS Group bought 135,789 Haemonetics shares in Q3 2026, an estimated $12.6M.
- Haemonetics made up 0.02% of UBS Group's portfolio in Q3 2026, its #991 holding.
- UBS Group first reported a position in Haemonetics in Q2 2013 and has held it in 54 quarters since.
- 361 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.